MARKET

BCDA

BCDA

Biocardia Inc
NASDAQ
1.200
+0.040
+3.45%
After Hours: 1.200 0 -0.01% 19:40 04/02 EDT
OPEN
1.200
PREV CLOSE
1.160
HIGH
1.200
LOW
1.140
VOLUME
93.99K
TURNOVER
--
52 WEEK HIGH
3.200
52 WEEK LOW
1.000
MARKET CAP
13.13M
P/E (TTM)
-0.9724
1D
5D
1M
3M
1Y
5Y
1D
BioCardia files request for meeting with FDA to discuss CardiAMP pathway
TipRanks · 3d ago
BIOCARDIA INC - EXPECTS FDA MEETING THIS QUARTER UNDER BREAKTHROUGH DESIGNATION FOR CARDIAMP SYSTEM
Reuters · 3d ago
BioCardia Seeks Accelerated FDA Pathway for CardiAMP HF
TipRanks · 3d ago
BIOCARDIA INC - PLANS FDA MEETING ON ACCELERATED APPROVAL PATHWAY FOR CARDIAMP SYSTEM IN HFREF - SEC FILING
Reuters · 3d ago
BioCardia seeks FDA meeting on accelerated approval pathway for CardiAMP in heart failure
Reuters · 3d ago
BioCardia Files Request for Meeting With FDA to Discuss Accelerated Approval Pathway for CardiAMP® System in Ischemic Heart Failure
Barchart · 3d ago
Weekly Report: what happened at BCDA last week (0323-0327)?
Weekly Report · 6d ago
Analysts Are Bullish on Top Healthcare Stocks: Nkarta (NKTX), BioCardia (BCDA)
TipRanks · 03/28 05:20
More
About BCDA
BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow, such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia. Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome. Its CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.

Webull offers BioCardia Inc stock information, including NASDAQ: BCDA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCDA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BCDA stock methods without spending real money on the virtual paper trading platform.